{"product_id":"pharmacoepidemiology-isbn-9781119413417","title":"Pharmacoepidemiology","description":"This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology. This edition has been fully revised and updated throughout and continues to provide a rounded view on all perspectives from academia, industry and regulatory bodies, addressing data sources, applications and methodologies with great clarity.Dieses Lehrbuch, ein wegweisender Klassiker, bietet in der 6. Auflage noch mehr Inhalte für Leser, die aktuelle Informationen zur Pharmakoepidemiologie benötigen. Die vorliegende Auflage wurde vollständig überarbeitet und aktualisiert. Sie bietet einen Überblick über sämtliche Facetten des Fachgebiets, aus Sicht von Lehre und Forschung, aus Sicht der Industrie und von Regulierungsbehörden. Datenquellen, Anwendungen und Methodiken werden verständlich erläutert. \u003cp\u003eContributors x\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003eAcknowledgments xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Introduction 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 What is Pharmacoepidemiology? 3\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies 27\u003cbr\u003e \u003ci\u003eJeffrey S. Barrett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies 44\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Sample Size Considerations for Pharmacoepidemiologic Studies 60\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 When Should One Perform Pharmacoepidemiologic Studies? 71\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II The Role of Pharmacoepidemiology in Different Sectors 81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6 The Role of Pharmacoepidemiology in the Healthcare System and Academia 83\u003cbr\u003e \u003ci\u003eJoshua J. Gagne and Jerry Avorn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 The Role of Pharmacoepidemiology in Industry 98\u003cbr\u003e \u003ci\u003eNicolle M. Gatto, Rachel E. Sobel, Jamie Geier, Jingping Mo, Andrew Bate, and Robert F. Reynolds\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 The Role of Pharmacoepidemiology in Regulatory Agencies 126\u003cbr\u003e \u003ci\u003eGerald J. Dal Pan, June Raine, and Shinobu Uzu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Pharmacoepidemiology and the Law 140\u003cbr\u003e \u003ci\u003eAaron S. Kesselheim and Kerstin N. Vokinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Sources of Data for Pharmacoepidemiology Research 165\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IIIa Spontaneous Reporting 167\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Postmarketing Spontaneous Pharmacovigilance Reporting Systems 169\u003cbr\u003e \u003ci\u003eGerald J. Dal Pan, Marie Lindquist, and Kate Gelperin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IIIb Electronic Data Systems 203\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Overview of Electronic Databases in Pharmacoepidemiology 205\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Encounter Databases 211\u003cbr\u003e\u003ci\u003eTobias Gerhard, Yola Moride, Anton Pottegård , and Nicole Pratt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Electronic Health Record Databases 241\u003cbr\u003e Daniel B. Horton, Harshvinder Bhullar, Lucy Carty, Francesca Cunningham, Alexis Ogdie, Janet \u003ci\u003eSultana, and Gianluca Trifiro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Inpatient Databases 290\u003cbr\u003e \u003ci\u003eJames A. Feinstein, Peter K. Lindenauer, Chris Feudtner, and Brian T. Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IIIc Studies Involving Ad Hoc Data Collection 305\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15 Event Monitoring in the UK 307\u003cbr\u003e \u003ci\u003eVicki Osborne and Saad A.W. Shakir\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Primary Data Collection for Pharmacoepidemiology 342\u003cbr\u003e \u003ci\u003eNancy A. Dreyer, Ana Filipa Macedo, and Priscilla Velentgas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IIId Choosing a Data Source 355\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17 Choosing among the Available Data Sources for Pharmacoepidemiology Research 357\u003cbr\u003e \u003ci\u003eBrian L. Strom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Selected Applications of Pharmacoepidemiology 373\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 Studies of Drug Utilization 375\u003cbr\u003e \u003ci\u003eBj\u003c\/i\u003e\u003ci\u003eörn Wettermark, Vera Vlahović-Palčevski, David Lee, and Ulf Bergman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Evaluating and Improving Physician Prescribing 411\u003cbr\u003e \u003ci\u003eChristine Y. Lu, the late Sumit R. Majumdar, Helene Lipton, and Stephen B. Soumerai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Pharmacoepidemiologic Studies of Vaccine Safety 437\u003cbr\u003e \u003ci\u003eRobert T. Chen, Jason M. Glanz, and Tom T. Shimabukuro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Epidemiologic Studies of Medical Devices: Methodologic Considerations for Implantable Devices 496\u003cbr\u003e \u003ci\u003eDanica Marinac‐Dabic, Sharon‐Lise Normand, Art Sedrakyan, and Thomas P. Gross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Research on the Effects of Medications in Pregnancy and in Children 524\u003cbr\u003e \u003ci\u003eDaniel B. Horton, Sonia Hernandez‐Diaz, Tamar Lasky, and Krista F. Huybrechts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Study of Biologics and Biosimilars 561\u003cbr\u003e \u003ci\u003eJeffrey R. Curtis and James D. Lewis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Risk Management 581\u003cbr\u003e \u003ci\u003eClaudia Manzo, Emil Cochino, Lubna Merchant, and Giampiero Mazzaglia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Distributed Networks of Databases Analyzed Using Common Protocols and\/or Common Data Models 617\u003cbr\u003e \u003ci\u003eSengwee Toh, Nicole Pratt, Olaf Klungel, Joshua J. Gagne, and Robert W. Platt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Comparative Effectiveness Research 639\u003cbr\u003e \u003ci\u003eSoko Setoguchi and Ian Chi Kei Wong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Data Mining and Other Informatics Approaches to Pharmacoepidemiology 675\u003cbr\u003e\u003ci\u003eAndrew Bate, Gianluca Trifirò, Paul Avillach, and Stephen J.W. Evans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Pharmacoepidemiologic Research on Drugs of Abuse 701\u003cbr\u003e \u003ci\u003eJana McAninch, Alex Secora, Cynthia Kornegay, and Judy Staffa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Selected Special Methodologic Issues in Pharmacoepidemiology 723\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e29 Assessing Causation from Case Reports 725\u003cbr\u003e\u003ci\u003eJudith K. Jones, Bernard Bégaud, and Elyse Kingery\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Molecular Pharmacoepidemiology 746\u003cbr\u003e \u003ci\u003eChristine Y. Lu and Stephen E. Kimmel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Bioethical Issues in Pharmacoepidemiologic Research 772\u003cbr\u003e \u003ci\u003eLaura E. Bothwell, Annika Richterich, and Jeremy Greene\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 The Use of Randomized Controlled Trials in Pharmacoepidemiology 792\u003cbr\u003e \u003ci\u003eRobert F. Reynolds, Samuel M. Lesko, Nicolle M. Gatto, Tjeerd P. van Staa, and Allen A. Mitchell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects 813\u003cbr\u003e \u003ci\u003eBrian L. Strom and the late Kenneth L. Melmon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Pharmacoeconomics: The Economics of Pharmaceuticals 837\u003cbr\u003e \u003ci\u003eKevin A. Schulman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Benefit–Risk Assessments of Medical Treatments 867\u003cbr\u003e \u003ci\u003eBennett Levitan, Rachael DiSantostefano, and Scott Evans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 The Use of Metaanalysis in Pharmacoepidemiology 897\u003cbr\u003e \u003ci\u003eJesse A. Berlin, Brenda J. Crowe, H. Amy Xia, and Stephen J.W. Evans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Validity of Drug and Diagnosis Data in Pharmacoepidemiology 948\u003cbr\u003e \u003ci\u003eMary Elizabeth Ritchey, Suzanne L. West, and George Maldonado\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Studies of Medication Adherence 991\u003cbr\u003e \u003ci\u003eJulie Lauffenburger, Trisha Acri, and Robert Gross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Risk Evaluation and Communication 1010\u003cbr\u003e \u003ci\u003eSusan J. Blalock, Rebecca Dickinson, and Peter Knapp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Methods for Studying the Health Effects of Drug–Drug Interactions 1030\u003cbr\u003e \u003ci\u003eSean Hennessy, Charles E. Leonard, Joshua J. Gagne, James H. Flory, Colleen M. Brensinger, and Warren B. Bilker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 The Pharmacoepidemiology of Medication Errors 1046\u003cbr\u003e \u003ci\u003eHanna M. Seidling and David W. Bates\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Patient Engagement and Patient‐Reported Outcomes 1061\u003cbr\u003e \u003ci\u003eEsi M. Morgan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies 1078\u003cbr\u003e \u003ci\u003eSebastian Schneeweiss and Samy Suissa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VI Conclusion 1109\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e44 The Future of Pharmacoepidemiology 1111\u003cbr\u003e \u003ci\u003eBrian L. Strom, Stephen E. Kimmel, and Sean Hennessy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAppendix A Sample Size Tables 1123\u003c\/p\u003e \u003cp\u003eAppendix B Glossary 1141\u003c\/p\u003e \u003cp\u003eIndex 1155\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eThe Editors\u003c\/b\u003e  \u003c\/p\u003e\u003cp\u003e\u003cb\u003eBrian L. Strom\u003c\/b\u003e is Chancellor, Rutgers Biomedical and Health Sciences and Executive Vice President for Health Affairs, Rutgers University, Newark, NJ, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eStephen E. Kimmel\u003c\/b\u003e is Professor of Medicine and Director of the Division of Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSean Hennessy\u003c\/b\u003e is Professor of Epidemiology and Director of the Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003ePharmacoepidemiology\u003c\/b\u003e SIXTH EDITION  \u003c\/p\u003e\u003cp\u003eStill the premiere reference text in the field, the sixth\u003csup\u003e \u003c\/sup\u003eedition of \u003ci\u003ePharmacoepidemiology\u003c\/i\u003e presents all of the latest information using a balanced survey of current research, data sources, applications, methods, and systems. Integrating multiple perspectives from academia, industry, and regulatory agencies, this comprehensive volume has been fully revised and updated to provide first-class guidance for anyone in need of up-to-date information on all aspects of pharmacoepidemiology. \u003c\/p\u003e\u003cul\u003e \u003cli\u003ePresents new and extensively revised, expanded, and updated material throughout\u003c\/li\u003e \u003cli\u003eOffers an increased global outlook and prominent international contributors\u003c\/li\u003e \u003cli\u003eProvides the most wide-ranging coverage of pharmacoepidemiology available\u003c\/li\u003e \u003cli\u003eDescribes various automated data systems and their respective advantages and shortcomings\u003c\/li\u003e \u003cli\u003eWritten and edited by world-renowned experts in the field\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003ePharmacoepidemiology\u003c\/i\u003e is the classic text on the subject and a must-have for pharmaceutical scientists and researchers, academics, educators, regulatory agencies, and related areas of drug safety and drug utilization research.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989773107429,"sku":"NP9781119413417","price":302.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119413417.jpg?v=1761785422","url":"https:\/\/k12savings.com\/products\/pharmacoepidemiology-isbn-9781119413417","provider":"K12savings","version":"1.0","type":"link"}